Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Allergic Reactions02:06

Allergic Reactions

32.0K
Overview
32.0K
Angina III: Clinical Manifestations and Assessment01:29

Angina III: Clinical Manifestations and Assessment

197
Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
197
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.3K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.3K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

393
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
393
Angina IV: Management01:26

Angina IV: Management

232
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
232

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Donidalorsen for the Treatment of Hereditary Angioedema: A Review of Clinical Studies.

Drug design, development and therapy·2026
Same author

Psychometric validation of the Angioedema Quality of Life Questionnaire (AE-QoL) for hereditary angioedema.

Journal of patient-reported outcomes·2026
Same author

Lonvoguran Ziclumeran - In Vivo CRISPR Gene Editing in Hereditary Angioedema.

The New England journal of medicine·2026
Same author

Surgeon Perceptions and Experiences with Postoperative Acute Pain Management: A Mixed-Methods Study.

Pain and therapy·2026
Same author

Switching Long-Term Prophylaxis to Donidalorsen for Hereditary Angioedema: 1-Year OASISplus Results.

Allergy·2026
Same author

Donidalorsen for hereditary angioedema: Long-term results from a 4-year, phase 2, open-label extension study.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026

Related Experiment Video

Updated: Jan 14, 2026

Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

9.3K

Association Between the Angioedema Control Test and Attack Frequency in Hereditary Angioedema.

Aaron Yarlas1, Alexandra J Feld2, Jakob B Bjorner2

  • 1Ionis Pharmaceuticals Inc., Carlsbad, California, USA.

Clinical and Translational Allergy
|January 12, 2026
PubMed
Summary

The Angioedema Control Test (AECT) accurately reflects hereditary angioedema (HAE) disease control. AECT scores correlate with HAE attack rates, validating its use in clinical practice.

Keywords:
AECTHAEdisease controlpatient‐reported outcomevalidity

More Related Videos

Measuring Local Anaphylaxis in Mice
07:49

Measuring Local Anaphylaxis in Mice

Published on: October 14, 2014

19.9K
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

1.3K

Related Experiment Videos

Last Updated: Jan 14, 2026

Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

9.3K
Measuring Local Anaphylaxis in Mice
07:49

Measuring Local Anaphylaxis in Mice

Published on: October 14, 2014

19.9K
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

1.3K

Area of Science:

  • Immunology
  • Genetics
  • Clinical Trials

Background:

  • Hereditary angioedema (HAE) causes unpredictable swelling attacks, impacting quality of life.
  • Assessing HAE disease activity and treatment response is challenging in routine care.
  • The Angioedema Control Test (AECT) is a patient-reported HAE disease control measure.

Purpose of the Study:

  • To evaluate the criterion validity of the AECT.
  • To assess the correlation between AECT scores and objective measures of HAE disease control, specifically HAE attack rate.

Main Methods:

  • Post-hoc analysis of the Phase 3 OASIS-HAE study (NCT05139810).
  • Patients with HAE received donidalorsen or placebo for 24 weeks.
  • Correlation between AECT scores and investigator-confirmed HAE attack rates was examined at baseline, week 12, and week 24.

Main Results:

  • AECT scores showed moderate to strong correlation with HAE attack rates (ρ = -0.40 to -0.85).
  • Significant differences in mean attack rates were observed between patients with poorly controlled (AECT < 10) and well-controlled (AECT ≥ 10) HAE.
  • Patients achieving complete disease control (AECT=16) had a 0 or 1 attack rate at week 24.

Conclusions:

  • The study supports the criterion validity of the AECT in patients with HAE.
  • AECT scores are strongly associated with objective measures of HAE disease control.
  • The AECT is a valuable tool for monitoring HAE disease control in clinical practice.